Summit Therapeutics
Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in the discovery, development, and commercialization of innovative antibiotics for serious infectious diseases. Established in 2003, the company primarily focuses on treating Clostridium difficile infection (CDI) with its lead product candidate, ridinilazole, which is currently undergoing Phase III clinical trials. Additionally, Summit is advancing its DDS-01 series to address infections caused by Neisseria gonorrhoeae and the DDS-04 series for Enterobacteriaceae. The company aims to establish its novel antibiotics as new standards of care, benefiting patients while also providing value to payors and healthcare providers. Summit Therapeutics operates primarily in the United States and Europe.
Discuva is a Cambridge (UK)-based Next Generation antibiotic discovery company with an experienced Pharma/Biotech management team and exceptional scientific pedigree. The company was established to address major gaps that exist in the current treatment of infective disease with antibiotics. Using proprietary methods which have come out of recent advances in genomic technologies, Discuva is developing targeted antibiotics against new emerging and drug-resistant pathogens.
DanioLabs
Acquisition in 2007
DanioLabs Ltd. discovers and develops therapeutics for neurological, ophthalmologic, metabolic, and gastrointestinal diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.